American Association for Cancer Research
cir-23-0480_figure_s12_supps12.png (2.17 MB)

Figure S12 from Neutralizing Antibodies Impair the Oncolytic Efficacy of Reovirus but Permit Effective Combination with T cell–Based Immunotherapies

Download (2.17 MB)
posted on 2024-03-04, 21:13 authored by Christianne Groeneveldt, Priscilla Kinderman, Lisa Griffioen, Olivia Rensing, Camilla Labrie, Diana J.M. van den Wollenberg, Rob C. Hoeben, Matt Coffey, Houra Loghmani, Els M.E. Verdegaal, Marij J.P. Welters, Sjoerd H. van der Burg, Thorbald van Hall, Nadine van Montfoort

Figure S12. Influx of immune cells after intratumoral Reo or VSV treatment of KPC3 tumors in Reo-preexposed or VSV-preexposed mice.


Leiden University Medical Center

Oncolytics Biotech (Oncolytics)

Stichting Overleven met Alvleesklierkanker (



Reovirus type 3 Dearing (Reo), manufactured for clinical application as pelareorep, is an attractive anticancer agent under evaluation in multiple phase 2 clinical trials for the treatment of solid tumors. It elicits its anticancer efficacy by inducing both oncolysis and intratumoral T-cell influx. Because most people have been preexposed to Reo, neutralizing antibodies (NAb) are prevalent in patients with cancer and might present a barrier to effective Reo therapy. Here, we tested serum of patients with cancer and healthy controls (n = 100) and confirmed that Reo NAbs are present in >80% of individuals. To investigate the effect of NAbs on both the oncolytic and the immunostimulatory efficacy of Reo, we established an experimental mouse model with Reo preexposure. The presence of preexposure-induced NAbs reduced Reo tumor infection and prevented Reo-mediated control of tumor growth after intratumoral Reo administration. In B cell–deficient mice, the lack of NAbs provided enhanced tumor growth control after Reo monotherapy, indicating that NAbs limit the oncolytic capacity of Reo. In immunocompetent mice, intratumoral T-cell influx was not affected by the presence of preexposure-induced NAbs and consequently, combinatorial immunotherapy strategies comprising Reo and T-cell engagers or checkpoint inhibitors remained effective in these settings, also after a clinically applied regimen of multiple intravenous pelareorep administrations. Altogether, our data indicate that NAbs hamper the oncolytic efficacy of Reo, but not its immunotherapeutic capacity. Given the high prevalence of seropositivity for Reo in patients with cancer, our data strongly advocate for the application of Reo as part of T cell–based immunotherapeutic strategies.